CSF2 and familial pancreatic carcinoma: In models of pancreatic cancer, the tumour-secreted cytokine, GM-CSF, has been identified as promoting MDSC differentiation.14, 18, 25 For this reason, targeting MDSC is of interest as a potential immunotherapy for cancer,46 with the aim of reversing immune suppression and promoting an anti-tumour immune response.